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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effectiveness of hearing aids for mild to moderate hearing loss in adults who have been prescribed at least one hearing
aid.
B A C K G R O U N D
Description of the condition
Hearing loss is the most prevalent sensory deficit (Mathers 2000);
it represents a major public health issue with substantial economi-
cal and societal costs. Untreated, adult hearing loss results in com-
munication difficulties that can lead to social isolation and with-
drawal, depression and reduced quality of life (Davis 2007). Hear-
ing loss is also associated with an increased risk of dementia (Lin
2011).
According to the World Health Organization hearing loss is the
13th most common global disease burden and the third leading
cause of years living with disease (WHO 2008). Disabling hearing
loss is estimated to affect 360 million persons globally (5.3% of
the world’s population) (WHO 2012a). The prevalence of hear-
ing loss increases with age (Akeroyd 2014), and given the ageing
society it is predicted that by 2030 adult-onset hearing loss will
be the seventh largest disease burden, above diabetes and human
immunodeficiency virus (HIV) (WHO 2008).
Epidemiological data suggest that the majority of cases of hear-
ing loss in adults are sensorineural (92%) and bilateral (94.8%)
(Cruickshanks 1998). There are numerous definitions of hearing
loss across different countries and organisations (Timmer 2015).
In this review, hearing loss is defined according to pure-tone thresh-
olds averaged across 0.5 kHz, 1.0 kHz, 2.0 kHz and 4.0 kHz in the
better-hearing ear, consistent with theWorldHealthOrganization
grades of hearing impairment (Mathers 2000). The majority of
hearing losses (92%) are those that are defined asmild or moderate
(AoHL 2015). Mild (or slight) hearing loss is indicated as 26 to
40 dB hearing level (HL) and described as the ability to hear and
repeat words spoken in a normal voice at one metre. Moderate
hearing loss is indicated as 41 to 60 dB HL and described as the
ability to hear and repeat words using a raised voice at one metre
(Mathers 2000). In addition to a loss of hearing sensitivity, there
may be additional sensory deficits of temporal and spectral pro-
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cessing that contribute to listening difficulties (Hopkins 2011),
not necessarily captured by pure-tone audiometry.
Description of the intervention
There are no effective medical or surgical treatments for mild to
moderate sensorineural hearing loss (Chisolm 2007), so the main
clinical intervention is the use of acoustic hearing aids (Kochkin
2009). It was estimated in 2012 that 11 million hearing aids were
soldworldwide (Kirkwood 2013).Hearing aids detect and amplify
sound and deliver an amplified acoustic signal via air conduction
to the external auditory canal on the same side as the signals are
detected. Hearing aids are described according to where they are
worn (e.g. behind-the-ear, in-the-ear, in-the-canal, completely-in-
the-canal) or classified by their technology (i.e. analogue, digitally
programmable analogue or digital hearing aids) (Dillon 2012).
Hearing aids are typically fitted by healthcare professionals who
have been trained in audiology or the dispensing of hearing aids.
Hearing aid fittings can be unilateral or bilateral and they are
typically programmed according to the user’s pure-tone hearing
thresholds usinghearing aid prescription formulae (Mueller 2005).
Changes to the hearing aid programme may be made according
to subjective preference for sound quality, such as the perceived
loudness of sounds (McArdle 2005). Hearing aid orientation that
includes information on hearing aid use and care, expectations
and limitations is typically offered as usual care (Boothroyd 2007;
Reese 2005).
The use of a hearing aid to amplify sounds does not necessar-
ily restore hearing function. Frequency response characteristics of
hearing aids, distortions arising from peak clipping, poor clarity
or loudness of speech can all have an impact on successful listen-
ing (Dillon 2012). As hearing aids amplify all sounds, not just
speech sounds, their use can lead to continued communication
difficulties following hearing aid fitting, particularly in noisy back-
grounds (Picou 2013). These and other reasons can lead to non-
use of hearing aids (McCormack 2013), with estimates of non-
use varying from 5% to 40%. Additional interventions may be
used to promote the use of hearing aids in people with hearing
loss (Barker 2014).
How the intervention might work
The primary function of hearing aids is to amplify and improve the
audibility of sounds, and speech in particular.However, improving
the audibility of sounds or speech signals forms only one element
within the broader concept of rehabilitating a person with hearing
loss, where the overall aim is to reduce the negative consequences
of hearing loss and improve communication. In order to commu-
nicate effectively, an individual needs to access the acoustic infor-
mation (hearing, a passive process), employ attention and inten-
tion (listening, an active process), correctly interpret the acoustic
and linguistic information (comprehension, a unidirectional pro-
cess) and use and transmit this information effectively (communi-
cation, a bidirectional process) (Kiessling 2003). These processes
can be mapped onto the International Classification of Function-
ing, Disability and Health (ICF, WHO 2001), which provides a
theoretical framework upon which to measure the success of am-
plification using hearing aids.
Based on the ICF Core Set (Danermark 2013), the goal of ampli-
fication with hearing aids where there is mild to moderate hearing
loss is to reduce the auditory deficits associated with body func-
tions and structures, thereby reducing activity limitations and par-
ticipation restrictions (Chisolm 2007; Kiessling 2003).
Improvements in the ability of a patient with hearing aids to detect
and discriminate sounds and speech can be measured by acoustic
outcomes (e.g. free-field threshold and speech audiometry). The
consequences of these improvements in terms of activities and
participation can then be measured by patient-reported outcomes
such as self report questionnaires, which can be defined as either
disease-specific (e.g. hearing) or generic (e.g. health-related quality
of life). Generic health-related quality of life measures generally
show limited benefit fromhearing aids as they lack sensitivity to the
consequences of hearing loss (Joore 2002; Joore 2003; Stark 2004).
There is, however, some evidence that the Health Utilities Index
Mark 3 (HUI3) is useful (Barton 2004; Davis 2007). Currently,
there is a lack of consensus on the optimal set of outcomemeasures
to use in hearing research (Granberg 2014).
Why it is important to do this review
Hearing aids are routinely offered and fitted for people with hear-
ing loss. It might seem axiomatic that such an intervention is
bound to be associated with an improvement in a patient’s ability
to hear and to communicate, but is this true? If there is an im-
provement in a patient’s ability to hear and communicate, how big
an improvement is it? There is little high-level evidence to answer
these questions and to inform discussions around the effectiveness
of hearing aids, their provision within a population and the ap-
proach to be taken by those who might fund such provision.
There are no recent or ongoing systematic reviews that provide
the high-level evidence to inform clinical decision-making on this
important topic. A previous systematic review of the published
evidence included randomised controlled trials (RCTs) and non-
randomised trials published up to August 2004 that met specific
criteria. It sought to address a specific objective: to determine if
the use of hearing aids compared to the non-use of hearing aids
resulted in improvements in health-related quality of life for adults
with sensorineural hearing loss using disease-specific and generic
instruments (Chisolm 2007). There were only two RCTs suitable
for inclusion at that time, limiting the generalisability of the find-
ings and the robustness of the conclusions.
This review will not compare the evidence for the bilateral versus
unilateral fitting of hearing aids, for which there is an ongoing
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Cochrane review (registered title: ’Unilateral versus bilateral hear-
ing aids for bilateral hearing impairment in adults’, Browning and
Whitmer).
O B J E C T I V E S
To evaluate the effectiveness of hearing aids for mild to moderate
hearing loss in adults who have been prescribed at least one hearing
aid.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials and quasi-ran-
domised studies, where the unit of analysis is the individual par-
ticipant. We will use the first treatment period of cross-over trials
and treat this as a parallel-arm trial, providing the study reporting
permits.
Types of participants
Adults (≥ 18 years old) with mild or moderate hearing loss, as
defined by pure-tone thresholds in the better-hearing ear averaged
across four frequencies (0.5 kHz, 1.0 kHz, 2.0 kHz and 4.0 kHz)
of 26 to 40 dB HL (mild hearing loss) and 41 to 60 dB HL
(moderate hearing loss). In the absence of confirmation that all
participants in a study meet these criteria (i.e. where participant-
level data are not reported or cannot be obtained), we will include
studies where the reported participant characteristics for the mean
four-frequency average fall within the range for either mild or
moderate hearing loss, as described above. If a mean frequency
average is offered for a combination of frequencies other than 0.5
kHz, 1.0 kHz, 2.0 kHz and 4.0 kHz, we will use studies where the
reported value falls between 26 to 40 dB HL (mild hearing loss)
and 41 to 60 dB HL (moderate hearing loss). If only qualitative
descriptions of mild and moderate hearing loss are given with no
supporting audiometric data, we will include such studies but will
not include them in the meta-analysis.
Types of interventions
Acoustic hearing aids, irrespective of where they are worn or the
type of technology (analogue or digital).
Wewill exclude hearing aids or implantable devices whose primary
purpose is to deliver bone conduction sound or those that detect
and deliver sound via air conduction to the contralateral ear.
The comparisons of interest are hearing aids versus either a passive
control (no intervention, waiting list control; we will pool these
in meta-analysis) or an active control that involves:
• information/education only, listening tactics and
communication training (we will pool these in meta-analysis);
• assistive listening devices; or
• auditory training (we will analyse these second two in
separate meta-analyses).
We will not consider studies where the intervention is delivered in
a group setting.
Types of outcome measures
We will analyse these outcomes in the review, but we will not use
them as a basis for including or excluding studies. We will analyse
the data at the trial endpoint, with a subgroup analysis to compare
different trial endpoints.
Primary outcomes
• Hearing-specific health-related quality of life, where
participation is the key domain. This will be measured using self
report questionnaires. If multiple questionnaires are used, we
propose a ranked hierarchy of instruments whereby we will
identify the primary outcome based on the following in order of
importance:
◦ Hearing Handicap Inventory for the Elderly (HHIE;
Ventry 1982) or HHI for Adults (HHIA; Newman 1990), if the
HHIE is not used;
◦ Quantified Denver Scale of Communication (QDS;
Tuley 1990);
◦ Auditory Disability Preference - Visual Analog Scale
(ADPI-VAS; Joore 2002); and
◦ any questionnaire not specified above that is relevant
to hearing-specific health-related quality of life.
• Adverse effect: pain. This may be reported by the patient as
pain, discomfort, tenderness or skin irritation, or may be
reported as occurrence of ear infection as a consequence of
hearing aid fitting.
Secondary outcomes
• Health-related quality of life. A ranked hierarchy of self
report outcome measures is proposed in the following order:
◦ Health Utilities Index Mark 3 (HUI-3; Furlong 2001);
◦ EQ-5D (Rabin 2001);
◦ SF-36 (Ware 1992), or if not reported other short
forms of the SF-36;
◦ Glasgow Benefit Inventory (GBI; Robinson 1996);
◦ World Health Organization Disability Assessment
Schedule (WHODAS; WHO 2012b);
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◦ Self-Evaluation of Life Function (SELF; Linn 1984);
and
◦ any questionnaire not specified above that is relevant
to health-related quality of life.
• Listening ability. A ranked hierarchy of self report outcome
measures is proposed in the following order:
◦ Abbreviated Profile of Hearing Aid Benefit (APHAB;
Cox 1995);
◦ Speech, Spatial and Qualities of Hearing (SSQ;
Gatehouse 2004);
◦ Glasgow Hearing Aid Benefit Profile (GHABP,
residual disability subscale; Gatehouse 1999); and
◦ any questionnaire not specified above that is relevant
to self report of listening ability.
• Adverse effect: noise-induced hearing loss, for example due
to over-amplification from inappropriate hearing aid fitting.
Search methods for identification of studies
The Cochrane ENT Trials Search Co-ordinator will conduct sys-
tematic searches for randomised controlled trials and controlled
clinical trials. There will be no language, publication year or pub-
lication status restrictions. We may contact original authors for
clarification and further data if trial reports are unclear and we will
arrange translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• Cochrane Register of Studies (CRS) ENT Trials Register
(search to date);
• Cochrane Central Register of Controlled Trials
(CENTRAL, current issue);
• Ovid MEDLINE (1946 to date);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations);
• PubMed (as a top up to searches in Ovid MEDLINE);
• Ovid EMBASE (1974 to date);
• EBSCO CINAHL (1982 to date);
• Ovid CAB abstracts (1910 to date);
• LILACS (search to date);
• KoreaMed (search to date);
• IndMed (search to date);
• PakMediNet (search to date);
• Web of Knowledge, Web of Science (1945 to date);
• CNKI (searched via Google Scholar to date);
• ClinicalTrials.gov (www.clinicaltrials.gov) (search via the
CRS to date);
• ICTRP (search to date);
• ISRCTN (www.isrctn.com) (search to date);
• Google Scholar (search to date);
• Google (search to date).
The subject strategies for databases will be modelled on the search
strategy designed for CENTRAL (Appendix 1). Where appropri-
ate, these will be combined with subject strategy adaptations of
the highly sensitive search strategy designed by Cochrane for iden-
tifying randomised controlled trials and controlled clinical trials
(as described in the Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011)).
Searching other resources
We will scan the reference lists of identified publications for addi-
tional trials and contact trial authors if necessary. In addition, the
Trials Search Co-ordinator will search PubMed, TRIPdatabase,
The Cochrane Library and Google to retrieve existing systematic
reviews relevant to this systematic review, so that we can scan their
reference lists for additional trials. We will search for conference
abstracts using the Cochrane ENT Trials Register and EMBASE.
Data collection and analysis
Selection of studies
Material downloaded from electronic sources will include details
of author, institution or journal of publication and abstract. MF,
DH and Fiona Barker (FB) will independently screen each study
against the criteria for including studies to determine their eligi-
bility for inclusion in the review. Where the decision about any
one study is not unanimous among the screening authors, we will
acquire the full article for further inspection. Once the full articles
are obtained, we will decide whether the studies meet the review
criteria. We will make a final decision by consensus.
Data extraction and management
MF and FB will independently extract data from the articles. We
will record the extracted data on a review-specific form that we
will develop and assess for suitability through pilot testing prior to
independent data extraction. Where data to be extracted are also
described in the text of an article, whether in themain body or in a
table, PK will resolve discrepancies between the two independent
extractions. Where data to be extracted are also described graphi-
cally in an article, we will use the average of the two independent
extractions provided there is agreement regarding their derivation
(see also Dealing with missing data).
Information to be extracted will include: trial design, setting,
methods of randomisation and blinding, power, inclusion and ex-
clusion criteria, type of intervention and control, time since hear-
ing aid fitting, and duration of follow-up, outcome measures and
statistical tests.
4Hearing aids for mild to moderate hearing loss in adults (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For both the intervention and control groups, data extraction will
include: baseline characteristics of participants (number, sex, age
and details of hearing loss (mean, standard deviation, range), and
details of any attrition or exclusion. For the intervention group we
will extract details of hearing aids (where worn, technology type,
manufacturer, unilateral or bilateral hearing aid fittings).
Outcome measure data to be extracted will include: group means
and standard deviations at pre- and post-intervention and follow-
up, number of participants and results of statistical tests of be-
tween-group comparisons.
We will contact the authors of a study should further information
be required, which cannot be extracted from the published report.
After independent data extraction byMF and FB,MEJ will review
the extracted data for disagreements, and revisit and discuss the
relevant studies with MF and FB until a consensus is reached.
Assessment of risk of bias in included studies
MF and PK will undertake assessment of the risk of bias of the
included trials independently, with the following taken into con-
sideration, as guided by theCochrane Handbook for Systematic Re-
views of Interventions (Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding of (i) participants and study personnel
(performance bias), and (ii) outcome assessment (detection bias);
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We will use the Cochrane ’Risk of bias’ tool in RevMan 5.3 (
RevMan 2014), which involves describing each of these domains
as reported in the trial and then assigning a judgement about the
risk of bias on the outcomes measured as a result of each entry:
’low’, ’high’ or ’unclear’ risk of bias.
Measures of treatment effect
We will express the size of the difference in treatment effect be-
tween a treatment group and a control group at a trial endpoint in
terms of the standardised mean difference (SMD). The calculation
of the effect size will use the pooled standard deviation. We will
also report the 95% confidence interval (CI) for each SMD. An
effect size greater than 0 indicates that a larger treatment effect was
observed in the treatment group relative to the control group. For
binary data, including adverse effects, we will preferably express
the treatment effects as risk ratios (RR).
Unit of analysis issues
The unit of analysis will be the participant. We do not anticipate
that participant-level data will generally be available, but suitable
summary statistics should be provided. As stated above, in the case
of cross-over trials we will only include the first period.
Dealing with missing data
We will make efforts to contact the corresponding author of an
included study to obtain any missing data. Where data can only
be estimated by reading off plots, we will achieve this as detailed
in the Data extraction and management section. If standard devi-
ations are not reported or provided by the authors we will estimate
standard deviations in RevMan 5.3 using available data, such as
standard errors, 95% CIs, P values and t values. If data are not
available for subgroups of interest then we will request these data
from study authors; likewise if data, for example, standard devi-
ations (or error bars on plots) are not available. Where missing
data cannot be obtained, we will describe the methodology used
to account for these missing data and investigate the mechanism
by which data might be missing (e.g. whether missing completely
at random). Where possible, we will perform analysis on an avail-
able case analysis basis, unless this is not feasible given the use of
imputation in individual studies. If possible, we will report the
extent of the missing data within studies.
Assessment of heterogeneity
We will assess heterogeneity among treatment effect sizes using
RevMan 5.3 (RevMan 2014), and we will express this in terms of
the I2 statistic. We will assess statistical significance using a Chi2
test with K-1 degrees of freedom. We will quantify heterogeneity
in terms of the I2 statistic with low, medium and high ranges of
0% to 40%, 41% to 60% and 61% to 100%, respectively.
Assessment of reporting biases
Wewill assess publication bias by examining a funnel plot in which
the size of treatment effects is plotted against their variability. We
will quantify deviation from the expected symmetrical pattern by
calculating the number of studies required to achieve symmetry
using the ’trim and fill’ method (Duval 2000).
Data synthesis
We will conduct random-effects meta-analyses of the SMDs using
RevMan 5.3 (RevMan 2014), as we anticipate significant hetero-
geneity across treatment effects between studies. For each meta-
analysis, we will report a summary effect size estimate in terms of
the SMD (and where appropriate risk ratio) together with its 95%
CI. We will calculate summary effects using the generic inverse
variance procedure.
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Subgroup analysis and investigation of heterogeneity
If heterogeneity is identified we will use subgroup analyses to as-
sess possible sources. These factors will include age at hearing aid
fitting, sex and degree of hearing loss (i.e. mild or moderate). De-
gree of hearing loss will be based on the better ear hearing thresh-
olds averaged across 0.5 kHz, 1.0 kHz, 2.0 kHz and 4.0 kHz and
we will classify this as mild and moderate for hearing thresholds
between 26 to 40 dB hearing level (HL) and 41 to 60 dB HL,
respectively. Where studies do not report separately by subgroup,
or do not fall completely within one particular subgroup, we will
allocate studies to a subgroup where there is evidence that a ma-
jority of participants fall within that group. Age will be defined
as older adults (> 55 years) and younger adults (<= 55 years). If a
study includes only one sex, we propose that those studies go en-
tirely into one subgroup, and if a study reports males and females
separately they can contribute to both subgroups of an analysis. If,
however, a study only reports a mixed group, then we will remove
this from the analysis. Time between fitting and trial endpointmay
also represent a source of heterogeneity and so a subgroup analysis
will also compare trials with endpoints at up to three months, over
three months to six months and six months or more.
Sensitivity analysis
We will perform sensitivity analyses to informally test the robust-
ness of assumptions from the data.
We will use sensitivity analyses where there is any uncertainty re-
garding any aspect of the included studies in terms of randomi-
sation (random/quasi-random), missing data (greater than 30%
at the primary endpoint) and description of hearing loss (mild/
moderate).
GRADE and ’Summary of findings’
PK and DH will use the GRADE approach to independently rate
the overall quality of evidence for each outcome. MF will then
review the ratings and discuss any disagreements with PK andDH,
involving other authors as required until a consensus is reached.
The quality of evidence reflects how confident we are that an
estimate of effect is correct.Wewill apply this to our interpretation
of results. The four possible ratings are: high, moderate, low or
very low. A rating of high-quality evidence implies confidence in
the estimate of effect and that further research is very unlikely to
change our confidence in the estimate. If a study is rated as very
low quality this would imply that the estimate of effect is very
uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of the these factors: study limitations (risk of bias), inconsistency,
indirectness of evidence, imprecision and publication bias.
We will include a ’Summary of findings’ table (Handbook 2011),
and we will use the GRADE considerations to separately assess
the quality of the body of evidence for each intervention and
primary outcome, and to draw conclusions about the quality of
evidence in the review. We will include the following outcomes
in the ’Summary of findings’ table: hearing-specific health-related
quality of life, health-related quality of life, listening ability and
adverse effects.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Hearing Loss] explode all trees
#2 MeSH descriptor: [Persons With Hearing Impairments] explode all trees
#3 hearing near (loss or impair*)
#4 deaf*
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Hearing Aids] this term only
#7 “hearing aid*” or hearing-aid* or “hearing device*” or “hearing instrument*” or “hearing system*”
#8 hearing near (loss or impair*) near (amplif* or aided or unaided)
#9 #6 or #7 or #8
#10 #5 and #9
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